SCHEMBL2982929

SCHEMBL2982929

Cc1cc(C)cc(NC(=O)c2ccc(Cl)c(S(=O)(=O)/N=C/N(C)C)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.51
▸ HTT P42858 5/20 0.51
▸ LMNA P02545 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.45
▸ STAT3 P40763 2/20 0.45
▸ THRB P10828 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2982932 1.00 MAPT (0.51) MAPTHTTLMNAKDM4ESTAT3
SCHEMBL9356442 0.80 LMNA (0.41) LMNAKDM4ECA1CA2ALDH1A1
SCHEMBL2981997 0.80 KMT2A (0.53) LMNAKDM4EALDH1A1SMN1; SMN2TSHR
SCHEMBL2981993 0.80 KMT2A (0.53) LMNAKDM4EALDH1A1SMN1; SMN2TSHR
SCHEMBL11542934 0.79 SMN1; SMN2 (0.56) MAPTHTTLMNACA1CA2
SCHEMBL2982687 0.79 CNR2 (0.46) MAPTHTTLMNACA1CA2
SCHEMBL2982682 0.79 CNR2 (0.46) MAPTHTTLMNACA1CA2
SCHEMBL11541849 0.76 ALDH1A1 (0.56) MAPTHTTLMNAKDM4ECA1
SCHEMBL939646 0.75 MMP2 (0.40) MAPTHTTLMNAALDH1A1SMN1; SMN2
SCHEMBL10857529 0.75 MAPT (0.52) MAPTHTTLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781613-B2 Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments SANOFI-AVENTIS (FR) 2010-08-24 — — US claimed
US-7781613-B2 Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments SANOFI-AVENTIS (FR) 2010-08-24 — — US disclosed
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS LIPE, STS, ARSA MAPT 4769/4885HTT 3896/4885LMNA 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback